In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large Stanford Medicine study finds the risk is low and not related to the CAR-T cells. A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy — a
Combining immune-targeted therapy with chemotherapy improves both progression-free survival and overall survival when compared to those who received regorafenib alone A study(Link is external) (Link opens in new window) led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival
Approval is based on findings from the QUILT 3.032 clinical trial, which was led by UCLA’s Dr. Karim Chamie The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of
Novartis presented data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen
Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body’s immune defenses against a cancer, have not been effective for GBM, in part because the tumor’s surrounding environment is largely impenetrable to assaults from the body’s immune system.
Noninvasive approach is fast, cost-effective and could be used to treat a variety of cancers doptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies
A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests, according to a study from Weill Cornell Medicine researchers. The discovery, reported Oct. 25 in the Journal
Researchers at the Keck School of Medicine of USC and the Cleveland Clinic Florida Research and Innovation Center have published new studies of GRP78, a protein implicated in both COVID-19 and multiple types of cancer, and a new drug that interferes with its effects. While vaccination can provide life-saving protection against COVID-19, scientists are
Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier, and more than 90 percent of GBM tumors return after being surgically removed, despite surgery and subsequent chemo- and radiation therapy being the most
Researchers at the University of California, Irvine and the Italian Institute of Technology have developed a new molecule, ALY101, that shows promising anti-cancer activity against a wide range of tumor cell types and in mouse models of a common type of melanoma. The findings, “Structure-based Design of CDC42 Effector Interaction Inhibitors for the Treatment of
